Key facts
- Zag Bio’s last known valuation is $25.0M (Jul 2023).
- It has raised $102.0M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($80.0M) in Oct 2025.
- Notable investors include Gaingels, Pear (California), Alexandria Venture Investments, The Engine, Exitfund — 17 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Zag Bio
Funding rounds
1 roundsAbout Zag Bio
Operator of a therapeutic platform intended to offer precise medicines for immune-mediated diseases. The company's platform specializes in discovering and developing therapies targeted directly to the thymus, to generate central immune tolerance, enabling professionals to transform the treatment of immune-mediated diseases.
- Industry
- Drug Delivery
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2022
- Employees
- 14
- Website
- zagbio.com/
- Ownership
- Privately Held (backing)
Zag Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zag Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zag Bio in its N-PORT filings yet. We sweep new filings monthly.